CN117065087A - Preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel - Google Patents
Preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel Download PDFInfo
- Publication number
- CN117065087A CN117065087A CN202311328925.4A CN202311328925A CN117065087A CN 117065087 A CN117065087 A CN 117065087A CN 202311328925 A CN202311328925 A CN 202311328925A CN 117065087 A CN117065087 A CN 117065087A
- Authority
- CN
- China
- Prior art keywords
- dfo
- black phosphorus
- chitosan
- temperature
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 67
- 239000000017 hydrogel Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims abstract description 68
- 229960000958 deferoxamine Drugs 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000001085 differential centrifugation Methods 0.000 claims abstract description 4
- 239000007791 liquid phase Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 34
- 239000002135 nanosheet Substances 0.000 claims description 24
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims description 18
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 238000002474 experimental method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000012154 double-distilled water Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000037314 wound repair Effects 0.000 claims description 4
- -1 N-methyl-2-pyrrolidone saturated NaOH Chemical class 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 239000010410 layer Substances 0.000 claims description 3
- 239000006193 liquid solution Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000005057 refrigeration Methods 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- PEMUISUYOHQFQH-UHFFFAOYSA-L disodium;1,3-dihydroxypropan-2-yl phosphate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].OCC(CO)OP([O-])([O-])=O PEMUISUYOHQFQH-UHFFFAOYSA-L 0.000 claims 1
- 239000002064 nanoplatelet Substances 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 6
- 241000588626 Acinetobacter baumannii Species 0.000 abstract description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 abstract description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract description 3
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 3
- 229960003085 meticillin Drugs 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000002131 composite material Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000002086 nanomaterial Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 206010051548 Burn infection Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 238000007626 photothermal therapy Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of hydrogel preparation, and provides a preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel, wherein the preparation method comprises the following steps: preparing Black Phosphorus Nanoplatelets (BPNs), chitosan (CS) temperature-sensitive hydrogel, preparing DFO (deferoxamine) solution and preparing black phosphorus chitosan DFO temperature-sensitive hydrogel, wherein the prepared black phosphorus nanoplatelets, chitosan hydrogel and DFO are mixed according to a specified mass ratio by adopting the steps of a liquid phase stripping method, an ultrasonic method, a differential centrifugation method and the like, so as to complete the preparation of the black phosphorus chitosan DFO temperature-sensitive hydrogel; through good photo-thermal effect after 808nm near infrared light irradiation, bacteria including methicillin-resistant staphylococcus aureus, multi-drug resistant pseudomonas aeruginosa and multi-drug resistant acinetobacter baumannii can be effectively inhibited from growing.
Description
Technical Field
The invention relates to the technical field of hydrogel preparation, in particular to a preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel.
Background
Infection is one of the most common causes of death in patients with severe burns, effectively preventing wound infection and promoting the healing rate of the wound surface of the patient is important for the treatment of the burn infection, and the clinically common treatment method of the burn wound surface is skin transplantation combined antibiotic treatment; in recent years, the overuse of antibiotics has led to the emergence of bacterial multidrug resistance, and these strains often form special biofilms to protect bacteria from antibacterial agents and phagocytosis, so the development of multifunctional biological nanomaterials has great significance for the comprehensive treatment of burn infections.
At present, phototherapy, particularly photothermal therapy (PTT) and photodynamic therapy (PDT) have wide application prospects in the aspects of preventing wound infection and promoting wound healing; in addition, since hydrogels have good biochemical effects, they also show attractive advantages in the field of wound dressings; thus, multifunctional light-responsive hydrogels (MPRHs) that integrate the advantages of light therapy and hydrogels are increasingly being used in biomedical applications, particularly in the field of wound repair.
The two-dimensional nano material has the unique characteristics of good mechanical flexibility, excellent conductivity, wide light absorption range, large surface area volume ratio and the like, and is widely focused in basic research and practical application. As a typical two-dimensional nanomaterial in the latter graphene era, black Phosphorus (BP) stands out in various nanomaterials, each of which has been covalently bound to 3 surrounding Phosphorus atoms by sp3 hybridization to form a pleated honeycomb structure. Mainly comprises black phosphorus quantum dots, black phosphorus nano particles and black phosphorus nano sheets (Black Phosphorus Nanosheets, BPNs). Black phosphorus nanoplatelets are ordered two-dimensional single-crystal nanoplatelets exfoliated from black phosphorus, are effective photosensitizers for generating singlet oxygen, with high quantum yields of about 0.91, and therefore, have positive application in catalysis and photodynamic therapy.
In the biomedical field, the honeycomb fold structure can effectively enlarge the drug loading rate of the medicament, the biomolecules and the developer, and the BP is easy to degrade in the physiological environment to generate nontoxic PxOy phosphate, so that compared with other two-dimensional materials, the BP has excellent biodegradability and biocompatibility and has good prospect of being applied to the biomedical field. Meanwhile, after the BPNs are irradiated by NIR, photon energy absorbed by the BPNs is emitted in a heat energy form, photo-induced heating is rapidly generated, and the exposed BPNs can be gradually degraded by surrounding oxygen and water.
The unique band gap structure of the BPNs enables the BPNs to have excellent photo-thermal heating performance, and the BPNs are hopeful to be applied to anti-infection treatment of bacteria as an alternative method of the existing antibiotics. The bactericidal mechanism of BPNs is mainly physical action to destroy cell membranes and to generate reactive oxygen species (reactive oxygen species, ROS). The photothermal effect of BP on bacterial destruction is considered another type of safe and effective method for treating bacterial infections, where near infrared light is able to penetrate deep into mammalian cells with minimal damage to normal cells. The sharp edges of BPNs can cause physical damage to the bacterial membrane, leading to RNA leakage and bacterial death; ROS produced by BP kill bacterial pathogens by the principle of destruction of cell membranes, bacterial intracellular molecules such as DNA, RNA and protein interactions. Both cause irreversible damage to the bacteria, and the various mechanisms of the synergistic effect can prevent the bacteria from evolving and avoid the initiation of drug resistance. At the same time, trace amounts of phosphate released by BP alter the metabolic state of bacteria (e.g., increase ATP flux), restoring them sensitivity to drugs from metabolically inactive states. When the concentration of BPNs is 100 mug/mL, the sterilizing effect of the BPNs on escherichia coli can reach 91.65% at maximum, and the sterilizing effect of the BPNs on bacillus subtilis can reach 99.69%. The BPNs require less amount and the generation of ROS requires less illumination time than other photosensitizers.
Compared with artificial synthetic materials, the natural medical material has better biocompatibility, is suitable for the growth, development and metabolism of cells, and is degradable. Chitosan (CS) is used as natural polymer polysaccharide with positive electricity, has wide sources, certain antibacterial activity and good biocompatibility, is often used as a matrix of wound dressing, is easy to chemically modify, and can be used for repairing, activating and coupling medicines. Moreover, the Beta-GP (Beta-glycihosphate) can form temperature-sensitive hydrogel by combining the Beta-GP (Beta-glycihosphate), and can provide an ideal microenvironment for wound healing.
Deferoxamine (DFO) activates HIF-1α to promote secretion of VEGF and SDF-1α, thereby accelerating vascularization. The research aims at developing a composite material with antibacterial activity and wound healing promoting function, and the composite healing promoting antibacterial dressing with uniformly embedded DFO is prepared by taking chitosan/beta-GP temperature-sensitive hydrogel as a base material and combining BP (back propagation) which is a multi-mode nano-drug two-dimensional material.
Disclosure of Invention
The invention provides a preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel, which are used for preparing a composite healing-promoting antibacterial dressing of uniformly embedded DFO by taking chitosan/beta-GP temperature-sensitive hydrogel as a base material and combining BP material, so as to solve the problems that a large amount of antibiotics are adopted in the current wound repair, bacterial drug resistance is easy to increase and the like.
The specific technical scheme of the invention is as follows:
a preparation method of black phosphorus chitosan DFO temperature-sensitive hydrogel comprises the following steps:
s1: preparing Black Phosphorus Nanoplatelets (BPNs), preparing the Black Phosphorus Nanoplatelets (BPNs) by liquid phase exfoliation, and exfoliating the Black Phosphorus Nanoplatelets (BPNs) in an organic solvent;
s2: preparing Chitosan (CS) hydrogel, namely dissolving 200mg of chitosan in 0.1M glacial acetic acid solution to prepare chitosan solution, and dropwise adding beta-GP solution into the prepared chitosan solution under uniform stirring to obtain clear and uniform liquid solution;
s3: preparing DFO (deferoxamine), weighing a specified weight of DFO, dissolving the DFO in sterile double distilled water, completing the preparation of a DFO solution and reserving the DFO solution for later use;
s4: and mixing the black phosphorus chitosan DFO temperature-sensitive hydrogel, and mixing the Black Phosphorus Nanosheets (BPNs), the chitosan hydrogel and the DFO prepared in the steps S1, S2 and S3 according to a specified mass ratio to prepare the black phosphorus chitosan DFO temperature-sensitive hydrogel.
As a further improvement of the present scheme, in step S1, the organic solvent is N-methyl-2-pyrrolidone (NMP).
As a further improvement of the scheme, in the step S1, the step of stripping the black phosphorus nanoplatelets by using the organic solvent N-methyl-2-pyrrolidone is as follows:
s1.1 firstly, adding 20mg of blocky black phosphorus into 20mL of N-methyl-2-pyrrolidone saturated NaOH solution;
s1.2, using an ultrasonic machine to ultrasonically treat the black phosphorus crystal powder solution for 10 hours in an ice bath environment to obtain brown suspension;
s1.3, adopting a differential centrifugation method to carry out centrifugation through a high-speed refrigerated centrifuge two-step method, centrifuging the ultrasonic dispersion liquid at 1000rpm for 20min, and removing the black phosphorus nano-sheets with more layers which are not completely stripped;
s1.4, taking supernatant, and further centrifuging at 15000rpm for 30min to obtain a single-layer black phosphorus nano-sheet;
s1.5 washing the centrifugal precipitate in the two steps with ultrapure water for 3 times to remove redundant solvents respectively, and finally preparing into 1mg/mL black phosphorus nanosheet aqueous solution for light-proof refrigeration storage for subsequent experiments.
As a further improvement of this scheme, in step S2, 560mg β -GP was dissolved in 1mL deionized water, both of which were pre-cooled at 4 ℃ for 10 minutes and then added dropwise to the chitosan solution.
As a further improvement of the scheme, in the step S2, the volume ratio of the chitosan to the beta-GP is 3:1, and the pH value of the mixed solution of the beta-GP and the chitosan is 7.20-7.40.
As a further improvement of this protocol, in step S3, 656.79ug of DFO was weighed and dissolved in 1mL of sterile double distilled water to prepare a 1mM DFO solution.
As a further improvement of the scheme, in the step S4, the black phosphorus chitosan DFO temperature-sensitive hydrogel consists of black phosphorus nano-sheets, 2% (w/v) chitosan, 56% (w/v) beta-GP and DFO, wherein the concentration of the black phosphorus nano-sheet solution is 20-75 mug/ml, and preferably 40 mug/ml. The concentration of the DFO solution is 1. Mu.M to 100. Mu.M, preferably 2. Mu.M.
The application of the black phosphorus chitosan DFO temperature-sensitive hydrogel is that the black phosphorus chitosan DFO temperature-sensitive hydrogel is applied to wound repair.
Compared with the prior art, the invention has the following beneficial effects:
1. the composite material has good photo-thermal effect after 808nm near infrared light irradiation, can effectively inhibit bacterial growth including methicillin-resistant staphylococcus aureus, multi-drug resistant pseudomonas aeruginosa and multi-drug resistant acinetobacter baumannii, and compared with common antibiotics, the novel hydrogel is not easy to generate drug resistance, but realizes antibiosis mainly through physical incised wound and photo-thermal effect, simultaneously promotes healing, effectively reduces the use of antibiotics, and reduces the harm of the use of antibiotics to human bodies.
Drawings
FIG. 1 is a flow chart of the preparation of hydrogels of the present invention;
FIG. 2 is a hydrogel scanning electron microscope of the present invention;
FIG. 3 is a graph showing the effect of the hydrogels of the present invention in the treatment of an infectious wound in mice;
FIG. 4 is a comparative graph of in vitro antimicrobial experiments of the present invention.
Detailed Description
Embodiments of the present invention are described in further detail below with reference to the accompanying drawings and examples. The following examples are illustrative of the invention but are not intended to limit the scope of the invention.
The invention provides a preparation method of black phosphorus chitosan DFO temperature-sensitive hydrogel, which comprises the following steps:
s1: preparing Black Phosphorus Nanoplatelets (BPNs), preparing the Black Phosphorus Nanoplatelets (BPNs) by liquid phase exfoliation, and exfoliating the Black Phosphorus Nanoplatelets (BPNs) in an organic solvent;
s1.1 firstly, adding 20mg of blocky black phosphorus crystals into 20mL of N-methyl-2-pyrrolidone saturated NaOH solution;
s1.2, using an ultrasonic machine to ultrasonically treat the black phosphorus crystal powder solution for 10 hours in an ice bath environment to obtain brown suspension;
s1.3, adopting a differential centrifugation method to carry out centrifugation through a high-speed refrigerated centrifuge two-step method, centrifuging the ultrasonic dispersion liquid at 1000rpm for 20min, and removing the black phosphorus nano-sheets with more layers which are not completely stripped;
s1.4, taking supernatant, and further centrifuging at 15000rpm for 30min to obtain a single-layer black phosphorus nano-sheet;
s1.5 washing the centrifugal precipitate in the two steps with ultrapure water for 3 times to remove redundant solvents respectively, and finally preparing into 1mg/mL black phosphorus nanosheet aqueous solution for light-proof refrigeration storage for subsequent experiments.
S2: preparing Chitosan (CS) hydrogel, namely dissolving 200mg of chitosan in 0.1M glacial acetic acid solution to prepare chitosan solution, dissolving 560mg of beta-GP in 1mL deionized water, pre-cooling for 10 minutes at 4 ℃, uniformly stirring, and then dropwise adding the solution into the prepared chitosan solution to obtain clear and uniform liquid solution; the volume ratio of the chitosan to the beta-GP is 3:1, and the pH value of the mixed solution of the beta-GP and the chitosan is 7.20-7.40.
S3: DFO (deferoxamine) preparation, weighing 656.79ug of DFO dissolved in 1mL of sterile double distilled water to prepare 1mM DFO solution and leaving for later use;
s4: mixing the black phosphorus chitosan DFO temperature-sensitive hydrogel, and mixing the black phosphorus nanosheets, the chitosan hydrogel and the DFO prepared in the S1, the S2 and the S3 according to a specified mass ratio to finish the preparation of the black phosphorus chitosan DFO temperature-sensitive hydrogel; wherein, the concentration of the black phosphorus nano-sheet solution is 20-75 mug/ml, preferably 40 mug/ml. The concentration of the DFO solution is 1. Mu.M to 100. Mu.M, preferably 2. Mu.M.
As shown in fig. 1, the black phosphorus/chitosan/DFO temperature-sensitive hydrogel consists of black phosphorus nanoplatelets, chitosan/beta-GP temperature-sensitive hydrogel and DFO, wherein the volumes of the components are as follows:
embodiment one:
after the black phosphorus chitosan DFO temperature-sensitive hydrogel is prepared by the method, the hydrogel is in a liquid state at a low temperature state and can form gel after 10min at room temperature of 37 ℃, as shown in fig. 2, the hydrogel can be observed to have a good space structure by a scanning electron microscope; in an in vitro experiment, as shown in fig. 4, the composite material has good photo-thermal effect after 808nm near infrared light irradiation, can effectively inhibit bacterial growth including methicillin-resistant staphylococcus aureus, multi-drug resistant pseudomonas aeruginosa and multi-drug resistant acinetobacter baumannii, and compared with common antibiotics, the novel hydrogel is not easy to generate drug resistance, realizes antibiosis mainly through physical incised wound and photo-thermal effect, and simultaneously gives consideration to healing promotion, and is a novel composite material.
Meanwhile, as shown in fig. 3, after a mouse infective wound surface model is prepared in a body experiment and is treated by black phosphorus/chitosan/DFO temperature-sensitive hydrogel, the wound surface area of a treatment group is obviously reduced and angiogenesis is increased compared with a control group; cell experiments also prove that the black phosphorus/chitosan/DFO temperature-sensitive hydrogel material can promote cell proliferation and migration, angiogenesis and macrophage polarization.
The embodiments of the present invention have been presented for purposes of illustration and description, but are not intended to be exhaustive or limited to the invention in the form disclosed, and although the invention has been described in detail with reference to the embodiments, it will be apparent to those skilled in the art that modifications may be made to the technical solutions described in the foregoing embodiments, or equivalents may be substituted for some of the technical features thereof.
Claims (8)
1. A preparation method of black phosphorus chitosan DFO temperature-sensitive hydrogel is characterized by comprising the following steps:
s1: preparing a black phosphorus nano sheet, preparing the black phosphorus nano sheet by adopting liquid phase stripping, and stripping the black phosphorus nano sheet in an organic solvent to prepare a black phosphorus nano sheet aqueous solution with the concentration of 1 mg/mL;
s2: preparing chitosan hydrogel, namely dissolving 200mg of chitosan in 0.1M glacial acetic acid solution to prepare chitosan solution, dropwise adding beta-GP solution into the prepared chitosan solution under uniform stirring to obtain clear and uniform liquid solution, wherein the name of beta-GP is sodium beta-glycerophosphate pentahydrate;
s3: preparing DFO, namely, the Chinese name of the DFO is deferoxamine, weighing a specified weight of the DFO, dissolving the DFO in sterile double distilled water, completing the configuration of a DFO solution and reserving the DFO solution for later use;
s4: and mixing the black phosphorus chitosan DFO temperature-sensitive hydrogel, and mixing the black phosphorus nanosheets, the chitosan hydrogel and the DFO prepared in the steps S1, S2 and S3 according to a specified mass ratio to finish the preparation of the black phosphorus chitosan DFO temperature-sensitive hydrogel.
2. The method for preparing the black phosphorus chitosan DFO temperature-sensitive hydrogel according to claim 1, wherein the method comprises the following steps: in step S1, the organic solvent is N-methyl-2-pyrrolidone.
3. The method for preparing the black phosphorus chitosan DFO temperature-sensitive hydrogel according to claim 2, wherein the method comprises the following steps: in the step S1, the steps of stripping the black phosphorus nano-sheets by using the organic solvent N-methyl-2-pyrrolidone are as follows:
s1.1 firstly, adding 20mg of blocky black phosphorus crystals into 20mL of N-methyl-2-pyrrolidone saturated NaOH solution;
s1.2, using an ultrasonic machine to ultrasonically treat the black phosphorus crystal powder solution for 10 hours in an ice bath environment to obtain brown suspension;
s1.3, adopting a differential centrifugation method to carry out centrifugation through a high-speed refrigerated centrifuge two-step method, centrifuging the ultrasonic dispersion liquid at 1000rpm for 20min, and removing the black phosphorus nano-sheets with more layers which are not completely stripped;
s1.4, taking supernatant, and further centrifuging at 15000rpm for 30min to obtain a single-layer black phosphorus nano-sheet;
s1.5 washing the centrifugal precipitate obtained in the two steps with ultrapure water for 3 times to remove redundant solvents, and finally preparing 1mg/mL black phosphorus nanosheet aqueous solution for light-shielding refrigeration storage for subsequent experiments.
4. The method for preparing the black phosphorus chitosan DFO temperature-sensitive hydrogel according to claim 1, wherein the method comprises the following steps: in step S2, 560mg of beta-GP is dissolved in 1mL deionized water, precooled for 10 minutes at 4 ℃, and then added dropwise to the chitosan solution.
5. The method for preparing the black phosphorus chitosan DFO temperature-sensitive hydrogel according to claim 4, wherein the method comprises the following steps: in the step S2, the volume ratio of the chitosan to the beta-GP is 3:1, and the pH value of the mixed solution of the beta-GP and the chitosan is 7.20-7.40.
6. The method for preparing the black phosphorus chitosan DFO temperature-sensitive hydrogel according to claim 1, wherein the method comprises the following steps: in step S3, 656.79ug of DFO was weighed and dissolved in 1mL of sterile double distilled water to prepare a 1mM DFO solution.
7. The method for preparing the black phosphorus chitosan DFO temperature-sensitive hydrogel according to claim 1, wherein the method comprises the following steps: in the step S4, the black phosphorus chitosan DFO temperature-sensitive hydrogel consists of a black phosphorus nano-sheet, 2% (w/v) chitosan, 56% (w/v) beta-GP and DFO, wherein the concentration of a black phosphorus nano-sheet solution is 20-75 mu g/ml, and the concentration of the DFO solution is 1-100 mu M.
8. The application of the black phosphorus chitosan DFO temperature-sensitive hydrogel is characterized in that the black phosphorus chitosan DFO temperature-sensitive hydrogel is applied to the field of wound repair.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311328925.4A CN117065087A (en) | 2023-10-16 | 2023-10-16 | Preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311328925.4A CN117065087A (en) | 2023-10-16 | 2023-10-16 | Preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117065087A true CN117065087A (en) | 2023-11-17 |
Family
ID=88717404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311328925.4A Pending CN117065087A (en) | 2023-10-16 | 2023-10-16 | Preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117065087A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117258031A (en) * | 2023-11-22 | 2023-12-22 | 中国人民解放军总医院第四医学中心 | Preparation method and application of A-PRF/BPNS/CS hydrogel |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060490A1 (en) * | 2003-01-07 | 2004-07-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Composition comprising a desferrioxamine-metal complex and its use for treating tissue damage following exposure to warfare agent |
| US20150309021A1 (en) * | 2001-05-16 | 2015-10-29 | Xrpro Sciences, Inc. | Advanced Drug Development and Manufacturing |
| CN107349478A (en) * | 2017-06-08 | 2017-11-17 | 西安交通大学 | Sodium glycero-phosphate/chitosan/polyethylene glycol sustained-release gel and its production and use |
| CN112188890A (en) * | 2018-04-15 | 2021-01-05 | 莫迪凯·舍维龙 | Compositions and methods for treating iron overload |
| CN114569789A (en) * | 2022-03-23 | 2022-06-03 | 宁波市医疗中心李惠利医院 | Preparation method and application of BPN-DFO gel scaffold |
| US20230075308A1 (en) * | 2020-05-27 | 2023-03-09 | Sinosteel Nanjing Advanced Materials Research Institute Co., Ltd. | Black phosphorus nanosheet, preparation method therefor, and application thereof |
| CN115887647A (en) * | 2022-11-01 | 2023-04-04 | 石河子大学 | Temperature-sensitive black phosphorus hydrogel for promoting wound healing and preparation method thereof |
-
2023
- 2023-10-16 CN CN202311328925.4A patent/CN117065087A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150309021A1 (en) * | 2001-05-16 | 2015-10-29 | Xrpro Sciences, Inc. | Advanced Drug Development and Manufacturing |
| WO2004060490A1 (en) * | 2003-01-07 | 2004-07-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Composition comprising a desferrioxamine-metal complex and its use for treating tissue damage following exposure to warfare agent |
| CN107349478A (en) * | 2017-06-08 | 2017-11-17 | 西安交通大学 | Sodium glycero-phosphate/chitosan/polyethylene glycol sustained-release gel and its production and use |
| CN112188890A (en) * | 2018-04-15 | 2021-01-05 | 莫迪凯·舍维龙 | Compositions and methods for treating iron overload |
| US20230075308A1 (en) * | 2020-05-27 | 2023-03-09 | Sinosteel Nanjing Advanced Materials Research Institute Co., Ltd. | Black phosphorus nanosheet, preparation method therefor, and application thereof |
| CN114569789A (en) * | 2022-03-23 | 2022-06-03 | 宁波市医疗中心李惠利医院 | Preparation method and application of BPN-DFO gel scaffold |
| CN115887647A (en) * | 2022-11-01 | 2023-04-04 | 石河子大学 | Temperature-sensitive black phosphorus hydrogel for promoting wound healing and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117258031A (en) * | 2023-11-22 | 2023-12-22 | 中国人民解放军总医院第四医学中心 | Preparation method and application of A-PRF/BPNS/CS hydrogel |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qi et al. | Engineering robust Ag‐decorated polydopamine nano‐photothermal platforms to combat bacterial infection and prompt wound healing | |
| Zhang et al. | Black phosphorus-loaded separable microneedles as responsive oxygen delivery carriers for wound healing | |
| Zhou et al. | A bioactive dextran-based hydrogel promote the healing of infected wounds via antibacterial and immunomodulatory | |
| Mei et al. | Augmented graphene quantum dot-light irradiation therapy for bacteria-infected wounds | |
| CN112121226B (en) | Composite hydrogel for promoting wound healing and preparation method and application thereof | |
| Shariati et al. | Graphene-based materials for inhibition of wound infection and accelerating wound healing | |
| CN113181421B (en) | Hydrogel wound dressing with antibacterial and immunoregulation functions and preparation method thereof | |
| CN117065087A (en) | Preparation method and application of black phosphorus chitosan DFO temperature-sensitive hydrogel | |
| Zhao et al. | Engineering a photosynthetic bacteria-incorporated hydrogel for infected wound healing | |
| Huang et al. | Highly antibacterial and adhesive hyaluronic acid hydrogel for wound repair | |
| CN113842497B (en) | Preparation method of CuS @ Cur hybrid hydrogel dressing with light-operated antibacterial and self-healing functions | |
| Liu et al. | Research progress on the use of micro/nano carbon materials for antibacterial dressings | |
| Liu et al. | NIR as a “trigger switch” for rapid phase change, on-demand release, and photothermal synergistic antibacterial treatment with chitosan-based temperature-sensitive hydrogel | |
| Ribeiro et al. | Application of stimulus-sensitive polymers in wound healing formulation | |
| Zhang et al. | Functional carbohydrate-based hydrogels for diabetic wound therapy | |
| Al Mamun et al. | Oxygen releasing patches based on carbohydrate polymer and protein hydrogels for diabetic wound healing: A review | |
| Zhang et al. | Application of hydrogels as carrier in tumor therapy: A review | |
| Liu et al. | Research progress on antimicrobial hydrogel dressing for wound repair | |
| Liang et al. | Natural hydrogel dressings in wound care: Design, advances, and perspectives | |
| Wang et al. | Organic–inorganic composite hydrogels: compositions, properties, and applications in regenerative medicine | |
| Gong et al. | A review of recent advances of cellulose-based intelligent-responsive hydrogels as vehicles for controllable drug delivery system | |
| Moreira et al. | New insights into biomaterials for wound dressings and care: Challenges and trends | |
| Liu et al. | Recent developments in stimuli‐responsive hydrogels for biomedical applications | |
| Hu et al. | Multifunctional photothermal hydrogels: Design principles, various functions, and promising biological applications | |
| Zhang et al. | Multicomponent Synergistic Antibacterial Hydrogel Based on Gelatin-Oxidized Carboxymethyl Cellulose for Wound Healing of Drug-Resistant Chronic Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |